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Methods: We developed a system for mechanical circulatory support based 
on the Jarvik 2000 intraventricular axial flow impeller pump (Jarvik 
Research, Inc., New York, N.Y.) and percutaneous electric power. The adult 
pump provides flow at a rate up to 10 L/min with an energy requirement of
7 to 10 watts. The device was implanted into the apex of the left ventricle 
through a left thoracotomy without cardiopulmonary bypass. A Dacron 
graft conveyed blood to the descending thoracic aorta. In patients, we will 
use a skull-mounted carbon pedestal to transmit fine electric wires through 
the scalp skin. Being highly vascular, the scalp skin is resistant to infection. 
Results: We tested 16 adult systems and one pediatric system in 17 adult 
ewes weighing between 60 and 90 kg. Five died of perioperative complica- 
tions. Twelve survived between 3 and 198 days (mean 44 days) with a 
functioning device. None of the sheep could receive adequate anticoagula- 
tion with warfarin (INR 1.0 to 1.5). Acute thrombotic occlusion occurred 
after a 3-hour power loss in one device (46 days) but was cleared with 
streptokinase. In a second animal with endocarditis, the pump inflow 
became occluded with vegetations. No other device-related problems or 
important hemolysis developed espite pump speeds between 10,000 and 
18,000 rpm. Renal function remained normal in all animals. Autopsy 
studies showed no pannus ingrowth at the device inflow despite the 
restrictive left ventricular cavity size. No sign of thromboembolism could be 
detected in the brains or kidneys. Conclusion: Our findings indicate the 
Jarvik 2000 Oxford System to be a safe and effective circulatory assist 
device. Potential uses include permanent circulatory support, bridge to 
transplantation, or bridge to myocardial recovery in acute or chronic left 
ventricular failure. (J Thorac Cardiovasc Surg 1997;114:467-74) 
W ith the proportion of elderly persons in the population increasing, heart failure is consum- 
ing enormous health care resources. Because of a 
severely restricted onor pool and a 5-year mortality 
of 40%, cardiac transplantation can no longer be 
considered to address the problem, l' 2 Mechanical 
blood pumps were first used clinically in the post- 
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cardiotomy setting, and their use was extended to 
bridge to transplantation. The critical shortage of 
donor hearts resulted in prolonged left ventricular 
support and the crucial finding that in some patients 
the myocardium showed the propensity to recov- 
er.3, 4 Bridge to recovery by mechanical off-loading 
offers a new approach to the treatment of heart 
failure, reminiscent of prolonged bed rest advocated 
by Burch and DePasquale 5 in the 1960s. Earlier 
application before the onset of wasting and multi- 
system failure may avert the need for transplanta- 
tion in some patients. 
Recently, the encouraging patient release pro- 
grams with the Thermo Cardiosystems, Inc. 
(Woburn, Mass.) and Novacor (Baxter Healthcare 
Corp., Novacor Div., Oakland, Calif.) left ventricu- 
lar assist devices (LVADs) in the United States have 
led to permanent implants for persons who are not 
candidates for transplantation in Europe. 6Although 
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Fig. 1. The Jarvik 2000 axial flow impeller pump (adult 
and pediatric) with ventricular cuff compared with the 
Jarvik 7 total artificial heart. 
these models are effective in this context, they are 
contraindicated for patients with less than 1.5 m 2 
body surface area, thus excluding small women and 
chi ldren] The stiff, percutaneous abdominal power 
line is a permanent infection risk, and removal of 
the LVAD is difficult when the patient's own heart is 
to be preserved. Efforts are therefore directed to- 
ward the design of a less obtrusive blood pump for 
widespread use in the various settings of acute and 
chronic heart failure, s' 9 A fully implantable system 
with transcutaneous power through induction coils 
will not be realized for some time. Consequently, we 
have developed a system based on the Jarvik 2000 
intraventricular impeller pump (Jarvik Research, 
Inc., New York, N.Y.) and a skull-mounted percu- 
taneous carbon pedestal to transmit he power line. 
The size of  the pump itself has been further reduced 
for use in infants and patients with acute myocardial 
infarction. 
Materials and methods 
The device and electrical system of the Jarvik 2000 
device is an axial flow impeller pump that is inserted 
through a cuff into the apex of the left ventricle (Fig. 1). 
An impervious Dacron graft conveys blood to the de- 
scending thoracic aorta (Fig. 2, A). The adult model 
measures 2.5 cm in diameter by 5.5 cm in length. The 
weight is 85 gm and the displacement volume 25 ml. The 
pediatric device measures 1.4 cm in diameter by 5 cm in 
length and is one fifth the size of the larger model. The 
weight is 18 gm and the displacement volume 5 ml. The 
electromagnetic pump consists of a rotor with impeller 
blades encased in a titanium shell and supported at each 
end by tiny blood-immersed ceramic bearings less than 1 
mm in diameter. The rotor is the sole moving part of the 
device. The impeller is powered by an electromagnetic 
field across the motor air gap, through which the blood 
flows. All blood-contacting surfaces are titanium. Power is 
delivered by a fine percutaneous wire and regulated by a 
pulse width-modulated, brushless, direct-current motor 
controller to determine motor speed. For the sheep 
devices, motor speed was at a fixed rate determined by the 
controller. (For the human model the motor rate will be 
responsive to heart rate and adjustable by the patient 
according to activity level.) 
At the site of exit through the skin, the fine electric 
cable is transmitted through a pyrolytic carbon button 
which, in patients, will be secured to the skull (Fig. 2, B). 
The combination of immobility and highly vascular scalp 
skin is known to resist infection in a percutaneous system 
for artificial hearing (Fig. 3). In vitro studies using a water 
glycerol test solution to simulate blood viscosity show the 
adult device to provide a flow rate of up to 10 L/min at 
18,000 rpm. At normal operating speeds of 10,000 to 
16,000 rpm, flow rates of between 4 and 6 L/rain are 
obtained at a mean aortic pressure of 80 mm Hg with a 
power requirement of 7 to 10 watts. 8 The device is 
inaudible to the unassisted ear but can be heard with a 
stethoscope. 
The animals. The adult ovine model was chosen in an 
attempt o extend survival beyond 6 months (the realistic 
experimental life span of calves in the Texas Heart 
Institute experiments). 9 For the adult device, 16 Welsh 
mule sheep between 3 and 5 years of age and weighing 
between 80 and 90 kg were used. For the "pediatric" 
pump implant the sheep weighed 60 kg. The surgical 
procedures and postoperative care were humanely under- 
taken by licensed personnel in compliance with Home 
Office (U.K.) guidelines. The animals were anesthetized 
with fentanyl, intubated, and their lungs ventilated with an 
inspired oxygen fraction of 100%. Two triple-lumen ve- 
nous catheters were introduced by cutdown on the left 
internal jugular vein, and a fine arterial catheter was 
introduced into the left common carotid artery. Arterial 
and venous blood pressures, together with the electrocar- 
diogram, were monitored continuously. Lidocaine infu- 
sion and boluses of bretylium were used to suppress left 
ventricular irritability during manipulation. Injections of 
the /3-blocker labetalol were used to lower the blood 
pressure during aortic side clamping. 
The operation. The sheep were positioned for a left 
thoracotomy. The seventh rib was removed to provide 
access to the left ventricular apex without excessive 
cardiac displacement. The power cable with a Dacron 
velour-covered carbon pedestal was tunneled under the 
scapula toward the midline and brought hrough the skin 
at the base of the neck. After intravenous antihypertensive 
therapy with labetalol was begun, 10,000 units of heparin 
was administered and an aortic side clamp applied. The 
preclotted 16 mm woven Dacron graft attached to the 
outflow of the Jarvik 2000 device was anastomosed to a 
longitudinal aortotomy with continuous 4-0 Prolene su- 
tures (Ethicon, Inc., Somerville, N.J.). The graft was 
clamped and the aortic side clamp removed. The pericar- 
dium was then opened wide and suspended by sutures 
from the wound edges. Access to the left ventricular apex 
was improved by placing a swab behind the heart. The 
silicone-reinforced Dacron sewing cuff was sutured 
around the pointed left ventricular apex with between 12 
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Fig. 2. A, The Jarvik 2000 Oxford System comprising pump, vascular graft, and percutaneous electrical 
system. B, The small electric cable is transmitted through the skin by way of a carbon pedestal screwed to 
the outer table of the skull to prevent movement. 
and 15 2-0 Ethibond mattress sutures (Ethicon) supported 
with Teflon pledgets. Lidocaine (1%) was injected irectly 
into the apical muscle before the excisional left ventricu- 
lotomy with a cork-bore type of coring knife. Blood loss 
through the open apex was controlled by rapid insertion of 
the pump through the sewing cuff and into the left 
ventricle. Uncrossmatched blood transfusion from donor 
sheep was used if required. The device was secured in the 
correct position by tying down umbilical tape purse-string 
ties integral with the sewing ring. The saline-filled outflow 
graft was vented to remove residual air and the pump was 
switched on. In the event of ventricular fibrillation during 
apical manipulations, pecially constructed elongated e- 
fibrillating paddles were applied to defibrillate. When 
hemodynamic stability was achieved, heparin was reversed 
with protamine, a chest drain was inserted, and the wound 
was closed. 
Postoperative care and investigations. The sheep were 
allowed to recover in the operating room and were 
transferred to unrestricted sheep pens before extubation. 
The animals were supervised constantly for at least 72 
hours after the operation. They were extubated between 2
and 12 hours after the operation. Arterial and venous 
pressures were monitored continuously for between 12 
and 24 hours along with the electrocardiogram. Initially, 
venous and arterial lines were maintained for 72 hours for 
blood sampling and antibiotic administration. With in- 
creasing experience, the lines and chest drain were re- 
moved between 12 and 24 hours after the operation. The 
capacity of the pump to capture all the pulmonary venous 
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Fig. 3. Carbon pedestal 15 years after implantation for 
artificial hearing. 
return and prevent opening of the aortic valve was tested 
by turning the device off and then progressively increasing 
the pump speed (up to 10 L/min) until the arterial 
pressure wave disappeared (Fig. 4). Battery power was 
used in six of the sheep to simulate the use of the device 
in patients. 
During the course of the experiments each device was 
maintained at a continuous speed of 10,000 to 12,000 rpm, 
with a calculated (nomogram) flow rate from 4 to 6 L/min. 
The system controller and electric ables were attached to 
a specially designed vest around the animal's back and 
forelegs (Fig. 5). All animals were free to move around 
the pen with battery or mains power conveyed through an 
overhead electric able attached to a fixed swivel appara- 
tus. Most animals were able to drink and eat hay and 
concentrates within 24 hours of the operation. 
The pump and electrical system were checked twice 
daily by auscultation a d recording of pump speed and 
power consumption. Power consumption was determined 
by recording voltage and amperes. These were recorded 
graphically from day to day to identify differences. The 
relationship between pump speed and flow has been 
published previously, s We did not use implantable flow- 
meters in our animals. Aspirin 75 mg daily and warfarin 20 
mg daily were commenced on the second postoperative 
day. Intramuscular analgesics were administered twice 
daily for 72 hours and thereafter for a specific indication. 
After removal of the arterial line, the pump function was 
monitored electrically and by auscultation. At weekly 
intervals, blood samples were obtained by percutaneous 
puncture from the internal jugular vein and assayed for 
full blood count, electrolytes, and indices of hemolysis 
including plasma-free hemoglobin and lactate dehydroge- 
nase. 
Autopsy studies. Autopsy was undertaken immediately 
after death and the cause of death was identified. The 
device was removed from the left ventricle and disassem- 
bled to look for thrombus formation. The heart, lungs, 
brain, kidneys, and liver were carefully examined for 
macroscopic evidence of thromboembolism. Slices of 
brain and kidney were examined histologically. 
Results 
Five deaths caused by arrhythmia or bleeding 
occurred within 24 hours of the operation. These 
procedures played an important part in the surgical 
learning curve. The intraoperative cardiac manipu- 
lations, particularly ventricular coring, provoked 
ventricular fibrillation in seven of the 17 animals. 
Conventional human defibrillating paddles were in- 
effective, and elongated paddles were designed. We 
eventually found that bretylium, given to reduce the 
likelihood of fibrillation during coring, initially 
caused supraventricular tachycardia. This predis- 
posed to ventricular fibrillation when given within 15 
minutes of ventricular coring. In later animals this 
problem was overcome by infusing bretylium shortly 
after anesthetic induction. No late deaths from 
ventricular fibrillation were attributable to the posi- 
tion of the device within the ventricle. Three of the 
five deaths within 24 hours were a direct result of 
refractory ventricular fibrillation and two were due 
to bleeding from the left internal thoracic artery and 
aortic anastomosis, respectively. One animal re- 
quired urgent reintubation when the rumen con- 
tents were regurgitated into the airway. A second 
sheep was resuscitated for this problem without 
reintubation. Three other sheep died of secondary 
hemorrhage from the aorta between the third and 
fifth postoperative days. These animals had initially 
made a straightforward postoperative r covery and 
were feeding normally. Bleeding was probably 
caused by severe hypertension at the time of re- 
moval of the arterial ine from the neck. In all of 
these sheep the device functioned well and was free 
from thrombus or blood clot at the time of autopsy. 
Modifications in technique avoided these complica- 
tions in subsequent animals. Two sheep died sud- 
denly at 12 and 22 days, respectively, of delayed 
aortic rupture, not at the anastomosis but at the site 
of side clamp application. Both devices were clean. 
Three animals were put to death at 34, 42, and 
48 days because of chronic infected hemothorax 
(n = 2) or drive-line infection (without he carbon 
pedestal). One of these animals had endocarditis 
with vegetations on the device and vascular graft. 
In this animal the power line had been fractured 
at the skin level 10 days before death, and the 
device was not functioning for 8 hours before 
repair. This may have accounted for thrombus in 
the pump and graft when the animal was put to 
death. The pumps were uninfected and clean in 
the other two. Four sheep are long-term survivors, 
alive between 6 weeks and 7 months (198 days) 
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Fig. 4. Capture of all mitral valve flow bythe intraventricular pump so that the aortic valve does not open. 
after the operation. Three have the adult device 
and one a miniaturized pediatric system. In each 
case the device is working satisfactorily. No de- 
vice-related eaths have occurred. 
Pump function. At the continuous speed of 
10,000 rpm the mean voltage requirement and am- 
perage for the adult device were 14 volts and 
between 50 and 150 milliamperes, respectively. The 
device was able to capture all the flow through the 
mitral valve, providing pulseless flow at speeds 
exceeding 12,000 rpm, at which point the mean 
arterial pressure was between 80 and 90 mm Hg. No 
adverse reaction occurred in the animals when 
blood flow changed from pulsatile to nonpulsatile. 
At 10,000 rpm, arterial pulse pressure remained in 
the region of 20 mm Hg but correlated with changes 
in pump current. Natural ventricular contraction 
provided a differential pressure load on the pump, 
and the torque load on the motor varied with pulse 
pressure. This variation in preload corresponding to
native heart function provided pulsatile flow. When 
the device was turned off during battery changes, the 
temporary reversal of graft flow (functional aortic 
insufficiency) was well tolerated by the animals. 
With the device running, we have not encoun- 
tered clotting or thromboembolism. When a second 
pump lost electrical power for 3 hours, presumed 
thrombosis prevented the restart. Thrombolysis with 
streptokinase, together with heparinization, re- 
stored normal pump function by electrical and aus- 
cultatory parameters. The sheep remained well 
throughout and survived for 198 days. 
The sheep's rumen precludes reliable anticoagu- 
lation, even with very high doses of warfarin. Most 
INR (international normalized ratio) results were 
between 1.0 and 1.5 and most animals had no 
measurable anticoagulation for most of their fol- 
low-up period. 
Early minor elevations of lactate dehydrogenase 
and free hemoglobin between 1 and 4 weeks after 
the operation may have resulted from the sequelae 
of uncrossmatched blood transfusion, drug adminis- 
tration, or resolution of intrathoracic hematoma 
after the operation. Alternatively, early hemolysis 
could have been related to the device or vascular 
graft, but no clinical or biochemical evidence for 
hemolysis was detected in long-term survivors. 
Autopsy studies. Presence of the device did not 
promote endothelial overgrowth or intracavity 
thrombus formation, even though the sheep were 
not given anticoagulants° 
On gross pathologic examination, two animals 
had diffuse consolidation i the left lung. Histologic 
examination revealed chronic inflammatory changes 
in the lungs with active bacterial infection, which 
were consistent with their intermittent fever and 
respiratory distress. No abnormalities were detected 
in the brain or liver in any animal. In extensive (5 
mm) histologic sections of the kidneys from seven 
animals that survived for more than 1 month, we 
found no evidence of thromboembolism, infarction, 
or infection. 
Discussion 
The animal model. Recovery after major cardio- 
vascular operations is difficult in the sheep model. 
Whereas calves tolerate surgical procedures well, 
the bovine model is restricted in longevity by rapid 
growth. We therefore decided to pursue the adult 
sheep model, and with increasing experience the 
length of survival improved. Our early problems 
with ventficular fibrillation were overcome by 
changing the time of bretylium administration. The 
problem of aortic rupture was thought to be the 
result of tissue fragility and was addressed by ob- 
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Fig. 5. Sheep, 6 months after implantation, wearing a vest with a controller and swivel electric cable 
connection. 
taining younger animals. Until this point we had 
been supplied with 5-year-old ewes that had been 
removed from the breeding stock. The younger ewes 
had perceptibly better tissues. 
We elected to avoid cardiopulmonary b pass de- 
spite the need to suture and core out the left 
ventricular apex while the heart supported the cir- 
culation. The sheep heart is thick walled and irrita- 
ble, with a small ventricular cavity (Fig. 6). The adult 
Jarvik 2000 device completely fills the left ventricu- 
far apex, and it was important to align the inflow of 
the pump with the mitral valve orifice. Despite the 
ventricular irritability during direct manipulations, 
the presence of the device within the ventricle did 
not cause death through late arrhythmia. 
Kaplon and colleagues 8 (Columbia Presbyterian 
Medical Center) implanted a smaller prototype device 
(1.8 cm diameter, 5 cm length, 45 gm weight, displace- 
ment volume 12 ml) into seven sheep using cardiopul- 
monary bypass in four. 8Two animals died in the early 
postoperative p riod, but five survived 57 -+ 18 days. 
Neither thromboembolic complications nor hemolysis 
developed in these animals, and mean hematocrit 
values rose significantly with time. Macris and cowork- 
ers 9 (Texas Heart Institute) implanted a prototype of 
the larger model (25 ml volume, 85 gm) into seven 
calves, which were supported for between 40 and 162 
days. 9 The animals were successfully given with warfa- 
rin, dipyridamole, and aspirin. Again, device-related 
hemolysis was minimal, and thrombus occurred in only 
one device, after which the rotor/stator junction was 
redesigned. The Oxford device is a later model based 
on the initial experience from these centers. 
The Jarvik 2000 Oxford System (Jarvik Research, 
Inc., New York, N.Y.). A system for human use has 
evolved uring the course of these experiments (Fig. 
2). This consists of the pump with an outflow 
Dacron graft (Hemashield, Meadox Medicals, Inc., 
Oakland, N.J.) for anastomosis to the descending 
thoracic aorta. Electrical wires will be brought out 
by way of the apex of the chest hrough the neck to 
the base of the skull, where a percutaneous, pyro- 
lytic carbon pedestal will transmit fine electrical 
wires through the skin of the scalp. The carbon 
pedestal is screwed to the outer table of the skull for 
complete immobility. The scalp is highly vascular 
and resistant to infection. A similar approach with 
artificial ear technology has been successful with 
very low infection rates for more than 15 years. A 
compact system controller is located externally in a 
vest or belt, together with lightweight batteries. 
The critical feature of the Jarvik 2000 design is 
that a high-flow stream of blood washes the tiny 
bearings continuously and prevents hrombus for- 
mation. After removal of the device, examination of 
the bearings howed virtually no wear. None of the 
three experimental centers has documented signifi- 
cant hemolysis or thromboembolism from the 
pump. In the animal with endocarditis n the current 
series, the inflow of the device was occluded by 
vegetations but little thrombus was found in the 
outflow. 
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The principal objective of these experiments was 
to address the safety, durability, and potential for 
thromboembolism or hemolysis. We have estab- 
lished mechanical reliability, remarkably little he- 
molysis, and freedom from thrombosis for up to 7 
months in an animal model in which reliable anti- 
coagulation is virtually impossible. Lack of percep- 
tible noise is also a great advantage in comparison 
with existing pusher-plate LVADs. The smaller pe- 
diatric device continued to function satisfactorily 20 
weeks after implantation. With the capacity to pump 
at a rate of 3 L/rain, this model can be used in 
infants with heart failure or in patients with myocar- 
dial infarction complicated by cardiogenic shock. 
Clinical potential for the Jarvik 2000 Oxford 
System. Our aim is to produce a realistic, tempo- 
rary or permanent substitute for the left ventricle 
suitable for use in both acute and chronic heart 
failure. Long-term off-loading of the left ventricle 
with existing LVADs during bridge to transplanta- 
tion has resulted in an element of myocardial recov- 
ery, particularly in patients with dilated cardiomy- 
opathy. 3'4 In Europe, removal of the LVAD in 
preference to transplantation has led to the concept 
of mechanical bridge to recovery. However, whereas 
removal of the existing LVADs is feasible in the 
transplant setting, where the native heart is excised, 
we have found removal of the Thermo Cardiosys- 
tems LVAD and conservation of the recovered 
ventricle to be technically challenging. 
In contrast o the electric pusher-plate LVADs, 
the compact axial flow impeller pump is silent, easily 
implantable, and unobtrusive. The intraventricular 
position conveys distinct advantages. The device is 
practically encapsulated by the native myocardium 
so that infection is unlikely. There is no inflow graft 
at risk for thrombus formation. Unlike the larger, 
implantable LVADs, the Jarvik 2000 system does 
not need valves and can be used in patients of all 
sizes.10, n Energy requirements areless than those 
of pusher-plate pumps, and an infection-resistant 
percutaneous electric cable has the advantage of 
simplicity and reliability. None of the animals with a 
percutaneous carbon pedestal had a drive-line infec- 
tion even though the skin was freely mobile at the 
exit site. 
This device has numerous potential uses, includ- 
ing permanent left ventricular support, bridge to 
cardiac transplantation, and bridge to left ventricu- 
lar recovery. Given the incontrovertible shortage of 
transplant donors, the prospect of realistic, perma- 
nent mechanical circulatory support or circulatory 
Fig. 6. Dissection of the sheep heart at autopsy showing 
the very thick left ventricular w lland small left ventric- 
ular cavity filled bythe device. 
support as a therapeutic option is compelling. Muel- 
ler and colleagues 12in Berlin have removed LVADs 
from patients with dilated cardiomyopathy who had 
been supported for 160, 244, 331, and 347 days. 
Disappearance of the autoantibody against he /31_ 
adrenergic receptor was used to time device explan- 
tation, and left ventricular ecovery has been sus- 
tained. 12 Two infants with acute viral myocarditis 
and ejection fractions less than 15% were resusci- 
tated by implantation of biventricular assist devices 
and were successfully weaned at 25 and 31 days with 
ejection fractions of 55% and 65%, respectively, 
thus avoiding transplantation. 13 Morphologic, bio- 
chemical, and functional myocardial recovery has 
been demonstrated in hearts with dilated cardio- 
myopathy after prolonged LVAD support at the 
Texas Heart Institute and Columbia Presbyterian 
Hospital. These hearts were studied in detail at 
the time of LVAD implantation and after removal 
at transplantation. 3' 4 Similar findings have now 
been reported from Osaka, Japan, and Oxford, 
United Kingdom. 14 
Besides long-term support, the Jarvik 2000 device 
is suitable for the treatment of postcardiotomy left 
ventricular failure or acute myocardial infarction 
with cardiogenic shock. In this setting the infant 
device could be used to provide up to 3 L of blood 
flow to off-load the failing ventricle. 
When the pacemaker was designed to treat prob- 
lems of heart rhythm during cardiac operations 40 
years ago, the real scope of the technology was 
unforeseen. It is only a matter of time before a 
blood pump emerges as a substitute for the left 
ventricle and becomes the mechanical equivalent to 
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the pacemaker in heart failure. The Jarvik 2000 
Oxford System approaches this goal. 
Mr. Clifford Hansen and the staff of the Biomedical 
Services Unit  provided invaluable technical assistance and 
expert humane care of the animals. 
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